Janus Henderson Group PLC Sells 788,379 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Janus Henderson Group PLC cut its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 13.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,100,288 shares of the medical research company’s stock after selling 788,379 shares during the quarter. Janus Henderson Group PLC owned about 5.35% of NeoGenomics worth $104,352,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Howland Capital Management LLC increased its position in shares of NeoGenomics by 2.9% during the 4th quarter. Howland Capital Management LLC now owns 31,337 shares of the medical research company’s stock worth $395,000 after purchasing an additional 888 shares during the last quarter. Marshall Wace North America L.P. increased its position in shares of NeoGenomics by 0.4% during the 3rd quarter. Marshall Wace North America L.P. now owns 220,059 shares of the medical research company’s stock worth $3,378,000 after purchasing an additional 934 shares during the last quarter. Legal & General Group Plc increased its position in shares of NeoGenomics by 10.0% during the 3rd quarter. Legal & General Group Plc now owns 10,559 shares of the medical research company’s stock worth $162,000 after purchasing an additional 963 shares during the last quarter. Ruggie Capital Group increased its position in shares of NeoGenomics by 74.1% during the 4th quarter. Ruggie Capital Group now owns 2,350 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Suntrust Banks Inc. increased its position in shares of NeoGenomics by 2.6% during the 4th quarter. Suntrust Banks Inc. now owns 39,959 shares of the medical research company’s stock worth $504,000 after purchasing an additional 1,028 shares during the last quarter. 84.27% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently commented on NEO shares. BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 20th. Needham & Company LLC restated a “buy” rating and set a $24.00 target price (up from $22.00) on shares of NeoGenomics in a report on Wednesday, May 1st. Zacks Investment Research upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a report on Tuesday, March 5th. Finally, CIBC upgraded NeoGenomics from a “neutral” rating to an “outperform” rating and lowered their target price for the company from $18.00 to $15.00 in a report on Tuesday, March 12th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $20.00.

In other news, VP Jennifer Balliet sold 30,000 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $19.57, for a total transaction of $587,100.00. Following the sale, the vice president now owns 40,000 shares of the company’s stock, valued at approximately $782,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Bonello sold 7,200 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $23.53, for a total value of $169,416.00. Following the sale, the insider now directly owns 13,935 shares in the company, valued at approximately $327,890.55. The disclosure for this sale can be found here. Insiders have sold a total of 382,876 shares of company stock worth $8,528,722 in the last three months. Corporate insiders own 12.20% of the company’s stock.

Shares of NEO traded down $0.19 during midday trading on Wednesday, hitting $21.21. The company had a trading volume of 606,108 shares, compared to its average volume of 1,174,724. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market capitalization of $2.02 billion, a PE ratio of 163.15 and a beta of 0.91. NeoGenomics, Inc. has a 1 year low of $11.05 and a 1 year high of $23.85.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. NeoGenomics had a positive return on equity of 3.07% and a negative net margin of 0.14%. The business had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $89.71 million. During the same quarter last year, the business posted $0.04 EPS. The business’s quarterly revenue was up 50.8% compared to the same quarter last year. Analysts predict that NeoGenomics, Inc. will post 0.19 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Janus Henderson Group PLC Sells 788,379 Shares of NeoGenomics, Inc. (NASDAQ:NEO)” was posted by Sundance Herald and is the sole property of of Sundance Herald. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://sundanceherald.com/2019/05/29/janus-henderson-group-plc-has-104-35-million-holdings-in-neogenomics-inc-neo.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: Average Daily Trade Volume – ADTV

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply